Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01190176
Other study ID # 113617
Secondary ID 2009-017282-35
Status Completed
Phase Phase 3
First received
Last updated
Start date September 12, 2011
Est. completion date September 20, 2017

Study information

Verified date October 2019
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is intended to provide up to a maximum of four years of annual oncogenic human papillomavirus (HPV) DNA testing and cervical cytology examination for NCT00294047 study subjects who displayed normal cervical cytology but tested positive for oncogenic HPV infection at their concluding NCT00294047 study visit.

Women who were pregnant at their concluding NCT00294047 study visit may also be included in this study, as no cervical sample could be collected at that visit.

The objectives and outcome measures of the primary phase (NCT00294047) are presented in a separate protocol posting.


Description:

Cervarix or Control [Al(OH)3] has been administered in the primary study NCT00294047.


Recruitment information / eligibility

Status Completed
Enrollment 34
Est. completion date September 20, 2017
Est. primary completion date September 20, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Female
Age group 28 Years and older
Eligibility Inclusion Criteria:

- Written informed consent obtained from the subject prior to enrolment.

- Subjects who the investigator believes that they can and will comply with the requirements of the protocol.

- A subject previously enrolled in the study NCT00294047 and who fulfils either of the following criteria:

- displayed normal cervical cytology but tested positive for oncogenic HPV infection at her concluding NCT00294047 study visit

- was pregnant so that no cervical sample could be collected at her concluding NCT00294047 study visit

Exclusion Criteria:

- A subject who at the NCT00294047 concluding study visit displayed normal cervical cytology and who was negative for oncogenic HPV infection at that visit.

- A subject who at the NCT00294047 concluding study visit had a cervical lesion at that visit or who had a cervical lesion that required treatment at her NCT00294047 exit colposcopy.

- A subject for whom the cervical cytology results from the concluding NCT00294047 study visit were unavailable for reasons other than pregnancy.

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Gynaecological follow-up
Subjects will receive a gynaecological follow-up with cytology and oncogenic HPV DNA testing every 12 months, for up to a maximum of four years.
Biological:
Cervarix
Subjects received 3 doses of the HPV vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule in the primary study HPV-015.
Placebo control
Subjects received 3 doses of the control [Al(OH)3] administered intramuscularly according to a 0, 1, 6 month vaccination schedule in the primary study HPV-015.

Locations

Country Name City State
Canada GSK Investigational Site Edmonton Alberta
Canada GSK Investigational Site Halifax Nova Scotia
Canada GSK Investigational Site Sherbrooke Quebec
Canada GSK Investigational Site Truro Nova Scotia
Canada GSK Investigational Site Vancouver British Columbia
Netherlands GSK Investigational Site Amsterdam
Netherlands GSK Investigational Site Rotterdam
Portugal GSK Investigational Site Almada
Portugal GSK Investigational Site Coimbra
Portugal GSK Investigational Site Lisboa
Portugal GSK Investigational Site Setúbal
Russian Federation GSK Investigational Site Moscow
Russian Federation GSK Investigational Site Sankt-Petersburg
Singapore GSK Investigational Site Singapore
Singapore GSK Investigational Site Singapore
United Kingdom GSK Investigational Site London
United Kingdom GSK Investigational Site Manchester
United States GSK Investigational Site Iowa City Iowa
United States GSK Investigational Site Wenatchee Washington
United States GSK Investigational Site Wichita Kansas

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

United States,  Canada,  Netherlands,  Portugal,  Russian Federation,  Singapore,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Number of Subjects Reporting Positive Oncogenic HPV DNA Results by Hybrid Capture II Test (HCII) at Month 12 Subjects with 2 positive oncogenic HPV DNA tests or 1 cervical cytology reading =ASC-US (atypical squamous cells of undetermined significance) positive for oncogenic HPV DNA or 1 cervical cytology reading =LSIL (low grade squamous intraepithelial lesion) were referred for colposcopy evaluation according to the clinical management algorithm. At Month 12 [12 months post concluding HPV-015 visit (Visit 9, Visit 11 or last HPV-015 study visit)]
Primary Number of Subjects Reporting Positive Oncogenic HPV DNA Results by Hybrid Capture II Test (HCII) at Month 24 Subjects with 2 positive oncogenic HPV DNA tests or 1 cervical cytology reading =ASC-US (atypical squamous cells of undetermined significance) positive for oncogenic HPV DNA or 1 cervical cytology reading =LSIL (low grade squamous intraepithelial lesion) were referred for colposcopy evaluation according to the clinical management algorithm. At Month 24 [24 months post concluding HPV-015 visit (Visit 9, Visit 11 or last HPV-015 study visit)]
Primary Number of Subjects Reporting Positive Oncogenic HPV DNA Results by Hybrid Capture II Test (HCII) at Month 36 Subjects with 2 positive oncogenic HPV DNA tests or 1 cervical cytology reading =ASC-US (atypical squamous cells of undetermined significance) positive for oncogenic HPV DNA or 1 cervical cytology reading =LSIL (low grade squamous intraepithelial lesion) were referred for colposcopy evaluation according to the clinical management algorithm. At Month 36 [36 months post concluding HPV-015 visit (Visit 9, Visit 11 or last HPV-015 study visit)]
Primary Number of Subjects Reporting Positive Oncogenic HPV DNA Results by Hybrid Capture II Test (HCII) at Month 48 Subjects with 2 positive oncogenic HPV DNA tests or 1 cervical cytology reading =ASC-US (atypical squamous cells of undetermined significance) positive for oncogenic HPV DNA or 1 cervical cytology reading =LSIL (low grade squamous intraepithelial lesion) were referred for colposcopy evaluation according to the clinical management algorithm. At Month 48 [48 months post concluding HPV-015 visit (Visit 9, Visit 11 or last HPV-015 study visit)]
Primary Number of Subjects With Any Cytological Abnormalities in Cervical Samples by ThinPrep PapTest at Month 12 Cytological abnormalities = atypical squamous cells of undetermined significance (ASC-US).
Cervical cytology was performed using the ThinPrep PapTest by Quest Diagnostics, or another GSK designated laboratory. Cervical cells for ThinPrep cytology were collected using the sampling device provided and rinsed into a collection vial containing PreservCyt medium.
At Month 12 [12 months post concluding HPV-015 visit (Visit 9, Visit 11 or last HPV-015 study visit)]
Primary Number of Subjects With Any Cytological Abnormalities in Cervical Samples by ThinPrep PapTest at Month 24 Cytological abnormalities = atypical squamous cells of undetermined significance (ASC-US).
Cervical cytology was performed using the ThinPrep PapTest by Quest Diagnostics, or another GSK designated laboratory. Cervical cells for ThinPrep cytology were collected using the sampling device provided and rinsed into a collection vial containing PreservCyt medium.
At Month 24 [24 months post concluding HPV-015 visit (Visit 9, Visit 11 or last HPV-015 study visit)]
Primary Number of Subjects With Any Cytological Abnormalities in Cervical Samples by ThinPrep PapTest at Month 36 Cytological abnormalities = atypical squamous cells of undetermined significance (ASC-US).
Cervical cytology was performed using the ThinPrep PapTest by Quest Diagnostics, or another GSK designated laboratory. Cervical cells for ThinPrep cytology were collected using the sampling device provided and rinsed into a collection vial containing PreservCyt medium.
At Month 36 [36 months post concluding HPV-015 visit (Visit 9, Visit 11 or last HPV-015 study visit)]
Primary Number of Subjects With Any Cytological Abnormalities in Cervical Samples by ThinPrep PapTest at Month 48 Cytological abnormalities = atypical squamous cells of undetermined significance (ASC-US).
Cervical cytology was performed using the ThinPrep PapTest by Quest Diagnostics, or another GSK designated laboratory. Cervical cells for ThinPrep cytology were collected using the sampling device provided and rinsed into a collection vial containing PreservCyt medium.
At Month 48 [48 months post concluding HPV-015 visit (Visit 9, Visit 11 or last HPV-015 study visit)]
Primary Number of Subjects With Referral to Colposcopy at Month 12 Detection was done on all subjects irrespective of their baseline HPV DNA status. At Month 12 [12 months post concluding HPV-015 visit (Visit 9, Visit 11 or last HPV-015 study visit)]
Primary Number of Subjects With Referral to Colposcopy at Month 24 Detection was done on all subjects irrespective of their baseline HPV DNA status. At Month 24 [24 months post concluding HPV-015 visit (Visit 9, Visit 11 or last HPV-015 study visit)]
Primary Number of Subjects With Referral to Colposcopy at Month 36 Detection was done on all subjects irrespective of their baseline HPV DNA status. At Month 36 [36 months post concluding HPV-015 visit (Visit 9, Visit 11 or last HPV-015 study visit)]
Primary Number of Subjects With Referral to Colposcopy at Month 48 Detection was done on all subjects irrespective of their baseline HPV DNA status. At Month 48 [48 months post concluding HPV-015 visit (Visit 9, Visit 11 or last HPV-015 study visit)]
Primary Number of Subjects With Referral to Treatment at Month 12 If a high-grade lesion was observed, the subject was referred to treatment according to local medical practice. Any further management following local cervical therapy for cervical lesions was handled according to local medical practice within the local health care system. After treatment, the subject's participation in the study ended. At Month 12 [12 months post concluding HPV-015 visit (Visit 9, Visit 11 or last HPV-015 study visit)]
Primary Number of Subjects With Referral to Treatment at Month 24 If a high-grade lesion was observed, the subject was referred to treatment according to local medical practice. Any further management following local cervical therapy for cervical lesions was handled according to local medical practice within the local health care system. After treatment, the subject's participation in the study ended. At Month 24 [24 months post concluding HPV-015 visit (Visit 9, Visit 11 or last HPV-015 study visit)]
Primary Number of Subjects With Referral to Treatment at Month 36 If a high-grade lesion was observed, the subject was referred to treatment according to local medical practice. Any further management following local cervical therapy for cervical lesions was handled according to local medical practice within the local health care system. After treatment, the subject's participation in the study ended. At Month 36 [36 months post concluding HPV-015 visit (Visit 9, Visit 11 or last HPV-015 study visit)]
Primary Number of Subjects With Referral to Treatment at Month 48 If a high-grade lesion was observed, the subject was referred to treatment according to local medical practice. Any further management following local cervical therapy for cervical lesions was handled according to local medical practice within the local health care system. After treatment, the subject's participation in the study ended. At Month 48 [48 months post concluding HPV-015 visit (Visit 9, Visit 11 or last HPV-015 study visit)]
See also
  Status Clinical Trial Phase
Terminated NCT01290393 - Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada
Completed NCT00369824 - Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects Phase 3
Completed NCT00345878 - Study to Evaluate the Immune Response and Safety of GSK Biologicals' HPV Vaccine in Healthy Women Aged 18-35 Years Phase 3
Completed NCT00947115 - Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects Phase 3
Completed NCT01187927 - Drug Use Investigation for Cervarix® N/A
Completed NCT00169494 - Human Papilloma Virus Vaccine Consistency and Non-inferiority Trial in Young Adult Women With GSK Bio HPV-16/18 Phase 3
Completed NCT00359619 - Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine Phase 2
Completed NCT00196937 - Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18 Phase 3
Completed NCT00534638 - Effectiveness, Safety and Immunogenicity of GSK Biologicals' HPV Vaccine GSK580299 (Cervarix) Administered in Healthy Adolescents Phase 4
Completed NCT00250276 - Evaluation of the Immune Responses of GSK Biologicals' HPV Vaccine Following Manufacturing Process Adaptation. Phase 3
Completed NCT01031069 - Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females Phase 4
Completed NCT00996125 - Immunogenicity and Safety Study of GSK Biologicals' Human Papillomavirus 580299 Vaccine in Healthy Female Subjects Phase 3
Completed NCT00779766 - Efficacy, Immunogenicity and Safety of GSK Biologicals' HPV GSK 580299 Vaccine in Healthy Chinese Female Subjects Phase 3
Completed NCT01953822 - Study Assessing Risk of Autoimmune Diseases in Females (9 - 25 Years) Exposed to Cervarix® in United Kingdom N/A
Completed NCT01153906 - Post-marketing Safety Study of Autoimmune Diseases Following Cervarix® Vaccination N/A
Completed NCT01207999 - Type Distribution of Human Papillomavirus in Adult African Women Diagnosed With Invasive Cervical Cancer N/A
Completed NCT00693615 - Safety and Immunogenicity Study of MEDI-517 (GSK 580299) With or Without Adjuvant in Healthy Adult Females Phase 2
Completed NCT00693966 - Dose-Comparison Study to Evaluate the Safety and Immunogenicity of MEDI-517 (GSK 580299) in Healthy Adult Females Phase 2
Completed NCT00541970 - Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs Phase 1
Completed NCT01627561 - Safety and Immunogenicity of GSK Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) in Healthy Female Children 4-6 Years Old Phase 3